The primary objective of this study was to assess whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfunction in diabetic patients with type 2 diabetes. For this purpose, adults aged between 45 and 75 years with a diabetes duration ≥ 5 years, and an ETDRS level ≤35 were randomly assigned to one of 3 arms: placebo, somatostatin and brimonidine. The primary outcome was the change in Implicit Time (IT) assessed by mfERG between baseline and at the end of follow-up (96 weeks). A total of 449 eligible patients were allocated to brimonidine (n=152), somatostatin (n=145) and placebo (n=152). When the primary end-point was evaluated in the whole population we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset of patients with pre-existing retinal neurodysfunction (34.7%), IT worsened in the placebo group (p<0.001), but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the topical administration of the selected neuroprotective agents appears useful in preventing the worsening of pre-existing retinal neurodysfunction. This finding points to screening retinal neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective treatment might be of benefit.
ABSTRACT
The primary objective of this study was to assess whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfunction in diabetic patients with type 2 diabetes. For this purpose, adults aged between 45 and 75 years with a diabetes duration ≥ 5 years, and an ETDRS level ≤35 were randomly assigned to one of 3 arms: placebo, somatostatin and brimonidine. The primary outcome was the change in Implicit Time (IT) assessed by mfERG between baseline and at the end of follow-up (96 weeks). A total of 449 eligible patients were allocated to brimonidine (n=152), somatostatin (n=145) and placebo (n=152). When the primary end-point was evaluated in the whole population we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset of patients with pre-existing retinal neurodysfunction (34.7%), IT worsened in the placebo group (p<0.001), but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the topical administration of the selected neuroprotective agents appears useful in preventing the worsening of pre-existing retinal neurodysfunction. This finding points to screening retinal neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective treatment might be of benefit.
INTRODUCTION
Diabetic retinopathy (DR) is classically considered a microvascular disease. However, growing evidence suggests that abnormalities in retinal function can be detected in patients without any evidence of microvascular abnormalities (1, 2) . In addition, it has been suggested that diabetesinduced retinal dysfunction might contribute to the development of microvascular abnormalities (2) . Therefore, it is reasonable to hypothesize that therapeutic strategies aimed at neuroprotection may also be effective in preventing the development and progression of microvascular disease. In fact, there is experimental evidence to support this concept (3, 4) .
In the early stages of diabetes a high proportion of patients present deficiencies such as decreased hue discrimination and contrast sensitivity, delayed dark adaptation, abnormal visual fields, and impairment of vision related quality of life (5) (6) (7) . Therefore, neuroprotection itself can be considered a therapeutic target, independently of its potential to prevent the development or progression of microangiopathy (8) .
A number of therapeutic strategies based on the main pathogenic mechanisms involved in neurodegeneration have been proposed (9) . Systemic administration of drugs blocking these pathways is very unlikely to reach the retina at pharmacological concentrations and, in addition, could have serious adverse effects. On the other hand, if the early stages of DR are the therapeutic target, aggressive treatments such as intravitreal injections would be unacceptable. Topical
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For Peer Review Only Diabetes treatment with neuroprotective agents in the form of eye drops has been neglected as a possible option because of a general assumption that the posterior chamber of the eye cannot be reached by this route. However, there is emerging evidence that several peptides administered by eye drops are able to reach the retina in pharmacological concentrations, at least in animal models (3, (10) (11) (12) (13) .
Topical administration has the advantage of concentrating drug action to the eye while potentially minimizing systemic effects.
On this basis we conducted the first clinical trial aimed at evaluating the effects of topically administered neuroprotective agents in diabetic patients with no or mild DR. The selected drugs were brimonidine and somatostatin, which have already shown their neuroprotective action in preclinical studies (11, 14) . The primary objective was to assess whether these drugs administered topically were able to prevent or arrest neurodegeneration as assessed by mfERG. The main secondary objectives were to evaluate their safety, and to examine their potential impact on the development or progression of DR in terms of microvascular disease.
METHODS

Study design and participants
In this randomized, placebo-controlled, phase II-III trial of parallel groups a total of 450 patients with type 2 diabetes were enrolled at 11 European centers belonging to the EUROCONDOR consortium. The trial (NCT01726075) was funded by the European Commission 7th Framework Programme. The protocol (Supplementary Material) was approved by the local research ethics committee at each site. All participants provided their written informed consent. Exclusion criteria were previously detailed (15) .
Randomization and masking
Eligible patients (n= 449) ( Supplementary Fig. S1 ) were randomly allocated in a 1:1:1 ratio to placebo, somatostatin 0.1%, and brimonidine tartrate 0.2% (1 drop BID in each eye in all cases).
Randomization was based on a minimization algorithm that balanced the three groups, stratified by ETDRS level (<20 vs. 20-35).
Procedures
Each patient underwent a comprehensive ophthalmic examination as previously reported (15) .
Only one eye from each patient was included in the study. If both eyes met the inclusion criteria, one of them was chosen randomly.
Multifocal ERG Recording and Analysis
The mfERGs were recorded in the study eye using the RETI-port/scan 21 (Roland Consult, Berlin, Germany) visual electrophysiology system. Detailed information regarding the methodology used has been previously reported (15) . 
Follow-up, outcome measurements and adverse events and compliance
Patients were followed and treated during a 96-week period. Study visits were scheduled as detailed in the protocol (Suppl Material) every 24 weeks.
The presence of neurodysfunction was defined as an eye with ≥6 altered hexagons for Implicit Time (IT) (16) . An altered hexagon was defined as a hexagon with a z-score 2 or higher for IT in comparison with a normative database that was previously created (17) . Safety evaluation included assessment of: intra-ocular pressure (IOP), BCVA, conjunctival redness, biomicroscopy, visual fields, blood pressure, heart rate and laboratory safety variables (i.e. blood count and blood biochemistry). In addition, reported adverse events such as overall drop discomfort were recorded.
A compliance of 60% was considered appropriate for this study. If compliance was below 60% or patients interrupted the study medication for more than 1 month, they were not evaluable for efficacy
Sample size calculation
Assuming that, at the end of the study, the placebo group would present 50% of abnormal mfERG IT versus 30% in the patients receiving the active drugs, the number of patients required in each group to demonstrate neuroprotection would be 93. However, as the progression of microvascular changes was also going to be analyzed, the progression rate for patients with very early ETDRS stages at study entry needed to be taken into account. Therefore, assuming that 30% of these patients would present some degree of worsening during the follow-up and that active therapy would reduce this figure to 15%, the number of patients required in each arm was 120. These estimates were performed to assess the efficacy of neuroprotective drugs (somatostatin or brimonidine) vs. placebo with a 2-side risk level of 0.05 and a statistical power of 80%. Taking into account a dropout rate of 20%, the final number of patients to be included in each arm would be 150.
Statistical analyses
For primary analyses (efficacy), we did the analyses per protocol (restricted to participants who completed the study) and by intention-to-treat. Pre-specified analyses for both the prevention and progression of neurodysfunction were performed. No imputations were done for missing data. The safety analysis population included the subjects who received at least one dose of study treatment. 
RESULTS
Baseline characteristics and drop-outs
Between February 5, 2013 and 6 November, 2013, eligible patients (n=449) with type 2 diabetes were randomized. The characteristics of the treatment groups at randomization were well balanced in terms of age, HbA1c and cardiovascular risk factors as previously reported (15) .
According to the pre-defined criteria of this study, we found only 156 (34.7%) patients with mfERG abnormalities at baseline (patients with neurodysfunction).
During the 2 years of follow-up a 24% (n=109) drop-out rate was observed, occurring mainly in the first year ( Supplementary Fig. S2 ). The characteristics of patients included in the analysis of efficacy per-protocol according to treatment are shown in Table 1 .
Safety
Detailed information of serious adverse events (SAEs) is shown in supplemental material (Tables   S1 and S2 ). Only 1 SAE (ocular hyperaemia) was considered related to the investigational drugs (brimonidine). The most frequent ocular adverse events are detailed in Supplementary Table S3 .
Brimonidine had more frequent adjudicated ocular adverse events.
Effectiveness
We did not find any significant effect of brimonidine or somatostatin in comparison with placebo on the number of abnormal hexagons during follow-up in the whole population when the analysis was performed per-protocol (Table 2) or by intention-to-treat (p=0.75 and p=0.24, respectively).
Pre-specified subanalyses were performed separately to examine the effects of the neuroprotective drugs in preventing neurodysfunction or arresting its progression. When patients without Page 8 of 34
For Peer Review Only Diabetes neurodysfunction at baseline were analysed, we did not find significant differences in the incidence of neurodysfunction at the end of the study. In contrast, both somatostatin and brimonidine were able to arrest the progression of pre-existing neurodysfunction. Therefore, those patients in whom some degree of neurodegeneration was already present (≥ 6 abnormal hexagons at the baseline), somatostatin and brimonidine were effective in preventing the increase of the mean IT that was observed in the placebo group ( Figure 1A) . However, when patients were analyzed per intentionto-treat a clear tendency to increasing the IT in the placebo group was also observed but did not reach statistical significance (p=0.06) ( Figure 1B ).
It is worth mentioning that there were no differences between the groups regarding the mean HbA1c during the trial. Therefore, our findings are not influenced by differences in the glycaemic control (Supplementary Table S4 and Table S5 ).
Regarding the main pre-specified secondary objectives, we did not find any effect of brimonidine or somatostatin in preventing or arresting microvascular disease.
Analyses of SD-OCT data revealed no difference in retinal thickness between the placebo, brimonidine or somatostatin arms at study entry or during follow-up (Table 3) .
DISCUSSION
The concept of DR as microvascular disease has evolved into that of a more complex diabetic complication in which neurodegeneration plays a significant role (8) . In fact, the American Diabetes Association has recently defined DR as a highly specific neurovascular complication (18) . This is the first clinical trial using neuroprotective drugs for treating DR. We have found that eye drops containing neuroprotective agents (brimonidine or somatostatin) did not exert any apparent effect in terms of primary prevention of neurodysfunction or in modulating the appearance and progression of microvascular disease, at least over 2 years of follow-up and using the methodology previously described. In the subgroup of patients with pre-existing retinal dysfunction, the agents tested were able to arrest the progression of IT only in patients who completed the study without any major protocol violations (per-protocol). Overall, our results suggest that topical administration of somatostatin or brimonidine failed in achieving the primary end point of this clinical trial.
However, the subset of patients with neurodysfunction could be envisaged as a promising target population in future clinical trials designed to elucidate this issue. The lack of effectiveness in preventing neurodysfunction could be attributed to the short follow-up (2 years) and to the excellent metabolic control of the patients included in the study.
The mechanisms by which brimonidine and somatostatin arrest the progression of neurodysfunction remain to be fully elucidated. Brimonidine has been shown to effectively promote the survival and function of retinal ganglion cells in a variety of animal models unrelated to diabetes (14) . This is the first study showing that topical administration of brimonidine arrests the progression of retinal neurodysfunction in patients with type 2 diabetes.
Somatostatin is abundantly produced by the human retina, the main source being the retinal pigment epithelium (19) . Somatostatin exerts relevant functions in the retina (20) . In the diabetic retina, a significant downregulation of somatostatin production has been reported (21-23).
Therefore, a replacement treatment by the topical route can be envisaged as a reasonable approach for treating DR. The main reasons by which systemic administration of somatostatin analogues failed in arrest progression of DR have been recently reviewed (20) , but one of the most important is their inability to cross the blood-retinal barrier.
Our results point to screening for retinal neurodysfunction as a critical issue to identify those patients in whom neuroprotective treatment might be of benefit. In this regard, mfERG is probably not a good option because it is a cumbersome and time-consuming method and, therefore, should be reserved for clinical trials. In addition, mfERG reflects only macular cone photoreceptor function and does not assess broader retinal integrity. Apart from mfERG other methods addressed to measure retinal function have been proposed (9) . Among these methods, fundus driven microperimetry is a very sensitive, reliable and rapid method and, consequently, can be a useful tool to screen for neurodysfunction in clinical practice (24, 25) .
Our study has several limitations. First, we found a lower prevalence of neurodysfunction than expected. Second, a low progression rate of microvascular disease was found. The inclusion by design of 43% of patients without any microvascular abnormalities at study entry, the short followup (2 years) and the excellent HbA1c and blood pressure levels throughout were the main factors accounting for this low rate of DR progression. Third, the drop-out rate was higher than anticipated (24% vs. 20%), but the number of patients who completed the study was higher than required to achieve the primary end point. Finally, there was no way to determine quantitatively whether or not somatostatin and bimonidine reached the human neurosensory retinas in meaningful concentrations.
In conclusion, we did not find any significant effect of topical administration of brimonidine or somatostatin in preventing or arresting both neurodysfunction and microvascular disease in the whole population included in this study. However, these neuroprotective agents could play a role in reducing the progression of pre-existing neurodysfunction. Further studies using new technologies and with longer follow-up addressed to confirm the neuroprotective effects in this subset of type 2 diabetic population, and whether they result in reduction of microvascular disease are needed.
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